Last reviewed · How we verify
NIC002
At a glance
| Generic name | NIC002 |
|---|---|
| Sponsor | Novartis |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking. (PHASE2)
- Improving the Efficacy of Anti-Nicotine Immunotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NIC002 CI brief — competitive landscape report
- NIC002 updates RSS · CI watch RSS
- Novartis portfolio CI